Investigating the effectiveness of the digital lifestyle intervention actensio to reduce blood pressure in adults with hypertension after six months of use - ACTENSIO

mementor DE GmbH0 个研究点目标入组 422 人开始时间: 2024年1月24日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Consent to participate in the clinical trial
•- Age over 18 years
•- Diagnosis of essential hypertension (practice SBP 140-179 mmHg and/or DBP 90-109 mmHg; 24-h SBP=130- mmHg and/or 24-h DBP=80)
•- Internet access and computer/smartphone compatible with actensio
•- Able to complete data collection and intervention
•- Ability to speak and read German
•- Antihypertensive medication (prescribed by a doctor) that has been stable over the last 3 months (i.e. not changed) or no antihypertensive medication
•- Possession of a blood pressure monitor
•- Patients are able to participate fully in the clinical trial and comply with the requirements for participation

•- Taking = 4 different classes of blood pressure medication
•- Practice SBP = 180 and/or DBP = 110
•- Life expectancy < 12 months
•- Cardiovascular event within the last 6 months (e.g. stroke, heart attack, cerebral haemorrhage)
•- Cancer diagnosis in the past 5 years or acute treatment with chemotherapy/immonosuppressants
•- Current or planned pregnancy during the clinical trial; breastfeeding women
•- cognitive impairment
•- Participation in another clinical drug trial or medical device trial
•- current or recent (within the last six months) participation in a lifestyle intervention programme (e.g. sports or diet programme)
•- Employees of mementor or another institution involved in the conduct/organisation/coordination/financing of the clinical trial
•- Relatives or life partners who have already participated in this clinical trial
•- Previous use of actensio

发起方

mementor DE GmbH